CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   997 Trials   3103 News 


«12...4567891011121314...5152»
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Journal, PD(L)-1 Biomarker:  Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. (Pubmed Central) -  Jul 9, 2024   
    Multivariate analysis results indicated that both early AFP response and AFP response independently predicted OS [hazard ratio (HR) 2.963, 95% confidence interval (CI) 1.333-6.585, p=0.008, and HR 6.182, 95% CI 1.780-21.466, p=0.004] and PFS (HR 2.186, 95% CI 1.107-4.318, p=0.024, and HR 3.078, 95% CI 1.407-6.730, p=0.005), serving as significant prognostic values. Early AFP response and AFP response serve as predictive biomarkers for the effectiveness of HAIC combined with lenvatinib and camrelizumab in patients with u-HCC.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer (clinicaltrials.gov) -  Jul 9, 2024   
    P2,  N=53, Active, not recruiting, 
    Carrelizumab combined with a modified TPF regimen has good efficacy and safety and can improve the LPR of locally advanced hypopharyngeal carcinoma. Trial completion date: Dec 2024 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Aug 2023
  • ||||||||||  Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases:  Cost-effectiveness of immune checkpoint inhibitors as a first-line therapy for advanced hepatocellular carcinoma: a systematic review. (Pubmed Central) -  Jul 5, 2024   
    The current evidence showed that ICIs, including atezolizumab plus bevacizumab, sintilimab plus bevacizumab/bevacizumab biosimilar, nivolumab, camrelizumab plus rivoceranib, pembrolizumab plus lenvatinib, tislelizumab, durvalumab, and cabozantinib plus atezolizumab, are probably not cost-effective in comparison with tyrosine kinase inhibitors or other ICIs...Our review demonstrated that ICIs were not a cost-effective intervention in advanced HCC. Although ICIs can significantly enhance the survival of patients with advanced HCC, decision-makers should consider the findings of economic evaluations and affordability before adoption of new therapies.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Review, Journal:  Camrelizumab-induced anaphylactic reaction: a case report and literature review. (Pubmed Central) -  Jun 28, 2024   
    Approximately 2?h after treatment, the patient's skin erythema subsided (vital sign monitoring SpO2 = 100%, BP = 122/84?mmHg, HR = 91 bpm and RR = 17 bpm); the patient did not complain about his obvious discomfort. Despite the rarity of acute anaphylactic reactions among immune-related adverse reactions, great importance should be given to anaphylactic reactions of camrelizumab due to its extensive clinical application.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jun 27, 2024   
    P2,  N=41, Recruiting, 
    Despite the rarity of acute anaphylactic reactions among immune-related adverse reactions, great importance should be given to anaphylactic reactions of camrelizumab due to its extensive clinical application. Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2024 --> Dec 2025
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Enrollment open, Trial completion date, Trial primary completion date:  DEB-TACE Combined With Apatinib and PD-1 for the Treatment of Intrahepatic Cholangiocarcinoma (clinicaltrials.gov) -  Jun 25, 2024   
    P2,  N=20, Recruiting, 
    Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2023 --> Apr 2025
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, sorafenib / Generic mfg.
    Journal, Metastases:  Sorafenib plus TACE with or without camrelizumab for the treatment of intermediate and advanced hepatocellular carcinoma. (Pubmed Central) -  Jun 19, 2024   
    Not yet recruiting --> Recruiting | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2023 --> Apr 2025 (1) Subgroup analysis demonstrated that TACE?+?sorafenib?+?camrelizumab could benefit HCC patients regardless of whether they had portal vein tumour thrombosis, Barcelona Clinic Liver Cancer B or C, or CHILD A or B; (2) We reported the immunotherapy-related AEs occurred with a significantly higher incidence in triple treatment, but all the AEs are tolerable.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Journal:  Bullous pemphigoid induced by camrelizumab. (Pubmed Central) -  Jun 6, 2024   
    TACE-TKI-ICI therapy contributed to better tumor control, PFS and OS than TKI-ICI therapy in unresectable HCC patients with first- or lower-order PVTT. No abstract available
  • ||||||||||  Review, Journal:  Immunotherapy for GTN: a new paradigm. (Pubmed Central) -  Jun 4, 2024   
    Priorities for future research include determining whether these agents have a role earlier in the disease course, the utility of combination with chemotherapy, and effects on future fertility. Treatment availability remains a concern due to the high price of these agents.
  • ||||||||||  ivaltinostat IV (CG-745) / CG Invites
    HDAC Inhibitor, CG-745 Inhibit EMT and Induce Apoptosis in Non-small Cell Lung Cancer (PS-25; Poster board no. 7) -  May 31, 2024 - Abstract #ERS2024ERS_4176;    
    Thus, we demonstrated the therapeutic efficacy of the new HDAC inhibitor, CG200745, in comparison with existing HDAC inhibitors, such as suberoylanilide hydroxamic acid (SAHA) in non-small lung cancer cells. It suggests that CG200745 could be a new treatment strategy for treatment of NSCLC.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment open, Trial completion date, Trial initiation date, Trial primary completion date:  bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC (clinicaltrials.gov) -  May 19, 2024   
    P=N/A,  N=40, Recruiting, 
    This article aims to Not yet recruiting --> Recruiting | Trial completion date: Sep 2025 --> Dec 2025 | Initiation date: Oct 2023 --> May 2024 | Trial primary completion date: Sep 2024 --> Jun 2025
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, AiRuiYi (fluzoparib) / Jiangsu Hengrui Pharma
    New P2 trial:  Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer (clinicaltrials.gov) -  May 13, 2024   
    P2,  N=117, Recruiting, 
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Review, Journal:  Challenges in autoimmune polyendocrine syndrome type 2 with the full triad induced by anti-programmed cell death 1: a case report and review of the literature. (Pubmed Central) -  May 6, 2024   
    A 60-year-old woman, without any personal or family history of autoimmune and endocrine diseases, started the immunotherapy of anti-PD1 (camrelizumab) for squamous cell carcinoma of the urethral meatus...Therefore, this patient met the diagnosis of APS-2 and was given multiple hormone replacement including glucocorticoid, levothyroxine and insulin therapy...A good prognosis can be obtained by appropriate replacement with multiple hormones. With the clinical application of ICPis to APS-2, the complexity of its treatment should be paid enough attention.
  • ||||||||||  Sulanda (surufatinib) / Hutchmed, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiKa (camrelizumab) / HLB Bio Group
    Trial primary completion date:  Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer (clinicaltrials.gov) -  Apr 30, 2024   
    P1/2,  N=83, Recruiting, 
    This study lays essential groundwork for developing precise neoadjuvant regimens. Trial primary completion date: Feb 2024 --> Jul 2024
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Keytruda (pembrolizumab) / Merck (MSD), AiRuiKa (camrelizumab) / HLB Bio Group
    New P2 trial, Checkpoint inhibition, IO biomarker:  ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI (clinicaltrials.gov) -  Apr 28, 2024   
    P2,  N=27, Not yet recruiting, 
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Retrospective data, Journal, Adverse events:  Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab. (Pubmed Central) -  Apr 26, 2024   
    This series underscores the importance of vigilant monitoring and a high index of suspicion for atypical hepatic lesions in patients undergoing treatment with PD-1 inhibitors. Further studies are warranted to elucidate the pathophysiology of this complication and to establish guidelines for the management and surveillance of patients receiving camrelizumab.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment open, Head-to-Head:  Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (clinicaltrials.gov) -  Apr 25, 2024   
    P3,  N=593, Recruiting, 
    Further studies are warranted to elucidate the pathophysiology of this complication and to establish guidelines for the management and surveillance of patients receiving camrelizumab. Not yet recruiting --> Recruiting